Covid-19 roundup: Mod­er­na gets the OK to use vac­cine in chil­dren ages 12-17; 23andMe finds ge­net­ic link to loss of taste and smell

Par­ents in Cana­da and Eu­rope now have two op­tions to pro­vide their chil­dren with a Covid-19 vac­cine.

Mod­er­na an­nounced that it has sub­mit­ted au­tho­riza­tion ap­proval for the use of its vac­cine in ado­les­cents with both Cana­di­an and EU health of­fi­cials on Mon­day. In May, the com­pa­ny an­nounced that the Phase II/III study of the vac­cine in chil­dren ages 12-17 met its pri­ma­ry end­points. The jab achieved 100% ef­fi­ca­cy in a study that in­volved 2,500 pa­tients who were ob­served un­der the same case de­f­i­n­i­tion in the Phase III study in adults.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER